Press Releases KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Real-time Estimate Cboe BZX Other stock markets 10:34:28 2024-04-29 am EDT			5-day change	1st Jan Change
11.05 ^USD	+2.50%		-3.50%	-9.88%

Apr. 22	Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors	CI
Apr. 15	Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors	Apr. 22	BU
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	Apr. 03	AQ
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	BU
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 02	BU
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	Mar. 18	BU
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine Designation for Sebetralstat	Mar. 13	AQ
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat	Mar. 12	BU
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update	Mar. 11	BU
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	Mar. 08	BU
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer	Mar. 07	BU
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference	Mar. 06	BU
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 04	BU
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma and Immunology Annual Meeting	Feb. 28	AQ
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma and Immunology Annual Meeting	Feb. 27	AQ
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting	Feb. 27	BU
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting	Feb. 26	BU
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat	Feb. 20	BU
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma and Immunology Annual Meeting	Feb. 19	AQ
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting	Feb. 16	BU
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants	Feb. 15	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Press Releases

Filters